Int Diag Hld Share Price (IDHC)

## [cite_start]IDHC Investment Analysis: "Buying Back In" [cite: 1, 3, 4]

[cite_start]The Oak Bloke’s analysis from May 5, 2026, details his decision to re-enter **Integrated Diagnostics Holdings (IDHC)** at a price of **$0.56 per share** following what he describes as "superb" FY2025 results[cite: 6, 51, 52, 53]. [cite_start]He views the company as an "efficiency engine" that is currently firing on all cylinders despite a complex regional environment[cite: 21, 22].

---

### Key Operational & Financial Highlights (FY2025)

[cite_start]The company demonstrated significant growth across its core metrics, proving its ability to pass on costs in a high-inflation environment[cite: 70, 79]:

* [cite_start]**Patient Growth**: IDHC served **9.4 million patients** in 2025, a 5% increase over the previous year[cite: 60, 61, 62, 70].

* [cite_start]**Testing Volume**: The group performed **43.5 million tests**, representing 11% year-on-year growth[cite: 56, 59, 70].

* [cite_start]**Network Expansion**: They added **139 new branches** during the period, bringing the total to 767[cite: 55, 58, 70].

* [cite_start]**Pricing Power**: Revenue per patient rose **31% to EGP 835**, and average revenue per test increased **24% to EGP 181**[cite: 70, 79, 80].

* [cite_start]**Profitability**: Net profit rose 28.8% to **£17.9 million**, though adjusted net profit (stripping out currency effects) actually surged by **79%**[cite: 107, 113, 115].

* [cite_start]**Margin Expansion**: Gross margins improved to **42.7%**, up 4.6 points from 2024[cite: 107].

* [cite_start]**Cash Position**: The business ended the year with **£23.1 million in cash** [cite: 126] [cite_start]after accounting for £7.4 million in dividends and capital expenditures for new branches[cite: 122, 129].

---

### Strategic Evolution

[cite_start]The Oak Bloke highlights a shift in IDHC's business model toward more sophisticated and defensive revenue streams[cite: 23]:

* [cite_start]**Digital Pivot**: The company has launched "digital healthcare" services, including home consultations, digital health records, and home prescription delivery[cite: 25, 27].

* [cite_start]**Specialized Services**: There is a growing focus on higher-value specialized diagnostics and radiology, which contributed to the 31% jump in revenue per patient[cite: 23, 73, 78, 80].

* [cite_start]**Geographic Turnaround**: While Egypt remains the primary profit driver [cite: 83, 96, 101][cite_start], Nigeria has reached an EBITDA-positive turning point [cite: 83, 95, 96][cite_start], and losses in Saudi Arabia (KSA) are narrowing as the expansion matures[cite: 83, 95, 96].

---

### The "Activist" Catalyst: Elliott Investment Management

[cite_start]A major theme in the "buying back in" thesis is the arrival of **Elliott Investment Management**, which acquired a **21.67% stake** in April 2026[cite: 135, 138, 142]. [cite_start]The Oak Bloke expects this "activist" presence to drive share price appreciation

Yea looks like a great business to me.. i bought a few yesterday

The recent sell off has made this a doozy of a buy here:

1. Strengthening / stable Egyptian Pound - so inflation risks deteriorating

2. Simple business - diagnostics. Saves people having to fly out to Asian destinations for medical tourism

3. Strong moat - no serious competitors. Meanwhile becoming more entrenched with its Hub, Spoke, Spike model

4. Upside as it rolls out into Saudi Arabia and Nigeria

DYOR but this seems like a nice entry point in fast-growing markets for a simple, cash generative Buffett like business

I read up about the company extensively then bought in in June at c. 36 cents.

Bottom line on this is look at the growth in the countries IDHC is operating in. Look at the margins, which then asks, does the company have a decent moat? Yes it does. For a simple business in healthcare.

Yet whenever I floated the idea everyone came back at me with negativity, including on a well-known smallcaps group. Risky, dangerous they said. Then look at the cr** they invest in.

No, it's stocks dependent on UK cashflows that are risky,

I also have a large position in ASA International - another one all the experts constantly slag off. Again, look at the moat, look ar Director buying and skin in the game (same as with IDHC). Look at the growth in the markets they operate in.

Buy these two companies and sell UK cr**, and you'll do just fine.

Another double over the next year for both, easy money.

This company just looks really good. Some of the posters on here now look rather foolish. Great results released today. SP up 29% and I'm up over 40% since punting a few £k so sold a third of my shares just now.

Credit to the Oak Bloke (blogs on Substack) who recommended we take a look at this one and his (free) in-depth analysis.